var data={"title":"Neomycin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Neomycin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6637?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=neomycin-drug-information\" class=\"drug drug_general\">see &quot;Neomycin: Drug information&quot;</a> and <a href=\"topic.htm?path=neomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Neomycin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709169\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Systemic absorption of neomycin occurs following oral administration, and toxic reactions may occur. Patients treated with neomycin should be under close clinical observation because of the potential toxicity associated with the use of neomycin. Neurotoxicity (including ototoxicity) and nephrotoxicity following the oral use of neomycin sulfate have been reported, even when used in recommended doses. The potential for nephrotoxicity, permanent bilateral auditory ototoxicity, and sometimes vestibular toxicity, is present in patients with healthy renal function when treated with higher doses of neomycin or for longer periods than recommended. Serial, vestibular and audiometric tests, as well as tests of renal function, should be performed (especially in high-risk patients). The risk of nephrotoxicity and ototoxicity is greater in patients with impaired renal function. Ototoxicity is often delayed in onset, and patients developing cochlear damage will not have symptoms during therapy to warn them of developing eighth nerve destruction, and total or partial deafness may occur long after neomycin has been discontinued.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Other factors which increase the risk of toxicity are advanced age and dehydration.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neuromuscular blockade:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular blockage and respiratory paralysis have been reported following the oral use of neomycin. The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics; neuromuscular-blocking agents such as tubocurarine, succinylcholine, decamethonium; or massive transfusions of citrate anticoagulated blood. If blockage occurs, calcium salts may reverse these phenomena, but mechanical respiratory assistance may be necessary.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Concurrent therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concurrent or sequential systemic, oral or topical use of other aminoglycosides, including paromomycin and other potentially nephrotoxic or neurotoxic drugs such as bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin, should be avoided because the toxicity may be additive.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. In addition, when administered intravenously (IV), diuretics may enhance neomycin toxicity by altering the antibiotic concentration in serum and tissue.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048863\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Ammonium Detoxicant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Aminoglycoside</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hyperammonemia Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443897\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Dosage expressed in terms of <b>neomycin sulfate</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Enteric bacteria eradication (including gut flora): </b>Limited data available: Birthweight &gt;1.2 kg: Oral: 50 to 100 mg/kg/day divided every 6 hours (Eichenwald 2017; Marks 1973; <i>Red Book</i> [AAP 2009]); <b>Note:</b> Absorption from the GI tract may occur, particularly with prolonged duration of therapy; do not use longer than 2 weeks.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048856\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=neomycin-drug-information\" class=\"drug drug_general\">see &quot;Neomycin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Dosage expressed in terms of <b>neomycin sulfate</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cholangitis, prophylaxis recurrent episodes after Kasai portoenterostomy:</b> Limited data available: Infants and Children &le;3 years: Oral: 25 to 50 mg/kg/day in 4 divided doses 4 days per week; continue until 2 to 3 years of age. Dosing based on a prospective, randomized, comparative trial and a small case series of patients &le;2 years of age at time of therapy initiation who had an episode of cholangitis after a Kasai portoenterostomy (n=10). In the trial, two prophylactic regimens were compared (neomycin vs trimethoprim/sulfamethoxazole) against historic controls; the mean age at time of therapy initiation was 6.1 &plusmn; 3.6 months; both neomycin and trimethoprim/sulfamethoxazole decreased cholangitis incidence by ~60% and neomycin increased survival. In the case series, dosing was started at 25 mg/kg/day or 50 mg/kg/day for 5 days just prior to discharge then given 4 days per week (4 days on, 3 days off) (Bu 2003; Lien 2015; Mones 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Enteric bacteria eradication (including gut flora)/infection: </b>Limited data available: <b>Note:</b> Use of neomycin for the treatment of enteric infection has been replaced by other agents; most contemporary use is for eradication of intestinal flora (<i>Red Book</i> [AAP 2015]). Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 12 g/<b>day</b> (Bradley 2017; Marks 1973; <i>Red Book </i>[AAP 2015]); duration of treatment should not exceed 2 weeks due to GI absorption which may result in systemic toxicities</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic encephalopathy:</b> Limited data available: Infants, Children, and Adolescents: Oral: 50 to 100 mg/kg/day divided every 6 hours for a maximum of 7 days with or without lactulose (Debray 2006; Lovejoy 1975); maximum daily dose: 12 g/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preoperative intestinal antisepsis: </b>Limited data available: Infants, Children, and Adolescents: Oral: 15 mg/kg/dose for 3 doses administered over 10 hours (eg, at 1 PM, 2 PM, and 11 PM) the day before surgery; maximum dose: 1,000 mg/dose (Bratzler 2013; Breckler 2010; Debo Adeyemi 1986; Feng 2015, Feng 2015a, Kliegman 2007; Pennington 2014; Rangel 2015); used in combination with other oral antimicrobial (eg, erythromycin or metronidazole) and with/or without adjunct to mechanical cleansing of the intestine (Feng 2015; Feng 2015a)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic hepatic insufficiency:</b> Oral: 4,000 mg/day for an indefinite period</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatic encephalopathy:</b> Oral: 500 to 2,000 mg every 6 to 8 hours or 4 to 12 g/day divided every 4 to 6 hours for 5 to 6 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Preoperative intestinal antisepsis:</b> Oral: 1,000 mg each hour for 4 doses then 1,000 mg every 4 hours for 5 doses; or 1,000 mg at 1 PM, 2 PM, and 11 PM with oral erythromycin on day preceding surgery as an adjunct to mechanical cleansing of the bowel; or 6 <b>g</b>/day divided every 4 hours for 2 to 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients: Dialyzable; there are no specific dosing adjustments provided in the manufacturer's labeling; however, based on experience with aminoglycosides in pediatric patients, renal impairment increases the risk for toxicity and consideration should be given to reducing the dose or discontinuing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosing adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200451\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200437\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25226338\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&ordm;C to 25&ordm;C (68&ordm;F to 77&ordm;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048866\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct therapy (with erythromycin) for the suppression of normal bacterial flora of the bowel (eg, preoperative preparation); adjunct therapy for hepatic coma (portal-systemic encephalopathy) by reducing ammonia-forming bacteria in the intestinal tract (All indications: FDA approved in ages &ge;18 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200504\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Sore mouth</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorectal pain, diarrhea, mouth irritation, nausea, rectal irritation, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Auditory ototoxicity, dyspnea, eosinophilia, nephrotoxicity, neurotoxicity, vestibular ototoxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200456\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to the neomycin or any component of the formulation; intestinal obstruction; patients with inflammatory or ulcerative GI disease.  Patients with a history of hypersensitivity or serious toxic reaction to other aminoglycosides may have a cross-sensitivity to neomycin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200441\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Malabsorption:  Small amounts of neomycin are absorbed through intact intestinal mucosa; increases in fecal bile acid excretion and reduction of intestinal lactase activity may occur. Oral doses of &gt;12 g/day produce malabsorption of fats, nitrogen, cholesterol, carotene, glucose, xylose, lactose, sodium, calcium, cyanocobalamin and iron. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity:<b> [US Boxed Warning]: May cause nephrotoxicity;</b> usual risk factors include preexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration. Discontinue treatment if signs of nephrotoxicity occur; renal damage is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular blockade and respiratory paralysis:<b> [US Boxed Warning]: May cause neuromuscular blockade and respiratory paralysis; </b> especially when given soon after anesthesia or muscle relaxants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: <b>[US Boxed Warning]: May cause neurotoxicity; </b>symptoms also include numbness, skin tingling, muscle twitching and seizures.  Usual risk factors include preexisting renal impairment and concomitant neuro-/nephrotoxic medications. Discontinue treatment if signs of ototoxicity occur; risk of hearing loss continues after drug withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hearing impairment: Use with caution in patients with preexisting vertigo, tinnitus, or hearing loss.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular disorders: Use with caution in patients with neuromuscular disorders, including myasthenia gravis and Parkinson disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with preexisting renal insufficiency; dosage modification required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Parenteral administration: More toxic than other aminoglycosides when given parenterally; <b>do not administer parenterally.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Surgical irrigation: <b>Do not use as  surgical irrigation</b> due to significant systemic absorption of the drug.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299750\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200446\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12634&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Arbekacin: May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): Neomycin may enhance the nephrotoxic effect of Bacitracin (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefazedone: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephradine: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distigmine: Aminoglycosides may diminish the therapeutic effect of Distigmine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mannitol (Systemic): May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Aminoglycosides may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: Aminoglycosides may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the ototoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.<b> Exceptions: </b>Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: Neomycin may decrease serum concentrations of the active metabolite(s) of Regorafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: Neomycin may decrease the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Products: Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200447\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5722064\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Aminoglycosides cross the placenta. Aminoglycosides may cause fetal harm if administered to a pregnant woman. There are several reports of total irreversible bilateral congenital deafness in children whose mothers received another aminoglycoside (streptomycin) during pregnancy. Although serious side effects to the fetus/infant have not been reported following maternal use of all aminoglycosides, a potential for harm exists. Large oral doses may cause malabsorption of some nutrients in the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048862\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function tests (serum creatinine, BUN, creatinine clearance); urinalysis for increased excretion of protein, decreased specific gravity, casts and cells; serial vestibular and audiometric tests </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22806842\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Toxic serum concentrations: &ge;1.5 mcg/ml (Marks 1973)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200440\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Interferes with bacterial protein synthesis by binding to 30S ribosomal subunits</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200455\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral, percutaneous: Poor (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: 97% of an orally administered dose remains in the GI tract. Absorbed neomycin distributes to tissues and concentrates in the renal cortex. With repeated doses, accumulation also occurs in the inner ear.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 0% to 30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak serum concentration: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (97% of oral dose as unchanged drug); urine (30% to 50% of absorbed drug as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22806843\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Each 500 mg neomycin sulfate tablet contains 350 mg of neomycin base.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2524688\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Neomycin Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $136.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F200458\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apokalin (NO);</li>\n      <li>Bykomycin (AT, CZ, DE);</li>\n      <li>Concatag (AR);</li>\n      <li>Cysto-Myacyne N (DE);</li>\n      <li>Endomixin (IT);</li>\n      <li>Enteromicina (PT);</li>\n      <li>Fradyl (BE, LU);</li>\n      <li>Glubacida (MX);</li>\n      <li>Minims Neomycin (BE, NL);</li>\n      <li>Myacyne (DE);</li>\n      <li>Nebacetin N Spruhverband (DE);</li>\n      <li>Nebapol B (AR);</li>\n      <li>Neo-Mix (AT);</li>\n      <li>Neomas (AR);</li>\n      <li>Neomicina (ES);</li>\n      <li>Neomycin (IL);</li>\n      <li>Neomycin Drossapharm (CH);</li>\n      <li>Neomycine (BE);</li>\n      <li>Neomycine Diamant (BE, FR, LU);</li>\n      <li>Neomycine Minims (NL);</li>\n      <li>Neomycinsulfat Chevita (AT);</li>\n      <li>Neomycinum (PL);</li>\n      <li>Nivemycin (GB, IE);</li>\n      <li>Ofodex (MX);</li>\n      <li>Rovicine (CH);</li>\n      <li>Sulfate de Neomycine-Chauvin (LU);</li>\n      <li>Trioft&iacute;n (MX);</li>\n      <li>Unguentum Neomycini (PL);</li>\n      <li>Uro-Beniktol N (CH);</li>\n      <li>Uro-Nebacetin N (DE);</li>\n      <li>Vagicillin (DE);</li>\n      <li>Vinacil (MX);</li>\n      <li>Vitacilina (MX);</li>\n      <li>Xyloderm (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). <i>Red Book: 2009 Report of the Committee on Infectious Diseases. </i>28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics; 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>, &quot;Antibacterial Drugs Dosage Tables&quot; 29th ed. Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics; 2012; 808-816.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &quot;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&quot; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Breckler FD, Rescorla FJ, Billmire DF. Wound infection after colostomy closure for imperforate anus in children: utility of preoperative oral antibiotics. <i>J Pediatr Surg</i>. 2010;45(7):1509-1513.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/20638534/pubmed\" target=\"_blank\" id=\"20638534\">20638534</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bu LN, Chen HL, Chang CJ, et al. Prophylactic oral antibiotics in prevention of recurrent cholangitis after the Kasai portoenterostomy.<i> J Pediatr Surg</i>. 2003;38(4):590-593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/12677572/pubmed\" target=\"_blank\" id=\"12677572\">12677572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: a critical review of the literature. <i>Paediatr Drugs</i>. 2002;4(12):817-837.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/12431134 /pubmed\" target=\"_blank\" id=\"12431134 \">12431134 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debo Adeyemi S, Tai da Rocha-Afodu J. Clinical studies of 4 methods of bowel preparation in colorectal surgery. <i>Eur Surg Res</i>. 1986;18(5):331-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/3093238/pubmed\" target=\"_blank\" id=\"3093238\">3093238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debray D, Yousef N, Durand P. New management options for end-stage chronic liver disease and acute liver failure. Potential for Pediatric Patients. <i>Pediatr Drugs</i>. 2006;8(1):1-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/16494508/pubmed\" target=\"_blank\" id=\"16494508\">16494508</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eichenwald EC, Hansen AR, Martin CR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott William and Wilkins; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feng C, Sidhwa F, Anandalwar S, et al. Contemporary practice among pediatric surgeons in the use of bowel preparation for elective colorectal surgery: A survey of the American Pediatric Surgical Association. <i>J Pediatr Surg</i>. 2015a; 50(10):1636-1640.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/26054862/pubmed\" target=\"_blank\" id=\"26054862\">26054862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feng C, Sidhwa F, Anandalwar S, et al. Variation in bowel preparation among pediatric surgeons for elective colorectal surgery: A problem of equipoise or a knowledge gap of the available clinical evidence? <i>J Pediatr Surg</i>. 2015;50(6):967-971.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/25818321/pubmed\" target=\"_blank\" id=\"25818321\">25818321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lien TH, Bu LN, Wu JF, et al. Use of <i>Lactobacillus casei</i> rhamnosus to prevent cholangitis in biliary atresia after kasai operation. <i>J Pediatr Gastroenterol Nutr</i>. 2015;60(5):654-658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/25534776/pubmed\" target=\"_blank\" id=\"25534776\">25534776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovejoy FH, Bresnan MJ, Lombroso CT, et al. Anticerebral oedema therapy in Reye&rsquo;s syndrome. <i>Archives of Disease in Childhood</i>. 1975;50:933-937.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/1220606/pubmed\" target=\"_blank\" id=\"1220606\">1220606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marks MI, Shapera M, Brazeau M. Pediatric antimicrobial therapy III. <i>Canadian Medical Association Journal</i>. 1973;109:213-214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/4728950/pubmed\" target=\"_blank\" id=\"4728950\">4728950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mones RL, DeFelice AR, Preud&rsquo;Homme D. Use of neomycin as the prophylaxis against recurrent cholangitis after Kasai portoenterostomy. <i>J Pediatric Surgery</i>. 1994;29(3):422-424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/8201512/pubmed\" target=\"_blank\" id=\"8201512\">8201512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neomycin tablets [prescribing information]. Boca Raton, FL: Breckenridge Pharmaceutical, Inc.; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pennington EC, Feng C, St Peter SD, et al. Use of mechanical bowel preparation and oral antibiotics for elective colorectal procedures in children: is current practice evidence-based? <i>J Pediatr Surg</i>. 2014;49(6):1030-1035.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/24888857/pubmed\" target=\"_blank\" id=\"24888857\">24888857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rangel SJ, Islam S, St Peter SD, et al. Prevention of infectious complications after elective colorectal surgery in children: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee comprehensive review. <i>J Pediatr Surg</i>. 2015;50(1):192-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/neomycin-pediatric-drug-information/abstract-text/25598122/pubmed\" target=\"_blank\" id=\"25598122\">25598122</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12634 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709169\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048863\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443897\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048856\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F200451\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F200437\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F25226338\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048866\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F200504\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F200456\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F200441\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299750\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F200446\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F200447\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5722064\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048862\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F22806842\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F200440\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F200455\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F22806843\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F2524688\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F200458\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12634|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=neomycin-drug-information\" class=\"drug drug_general\">Neomycin: Drug information</a></li><li><a href=\"topic.htm?path=neomycin-patient-drug-information\" class=\"drug drug_patient\">Neomycin: Patient drug information</a></li></ul></div></div>","javascript":null}